Intercept Pharmaceuticals (ICPT -0.8%) says it's completed the enrollment for its Phase III...

|About: Intercept Pharmaceuticals (ICPT)|By:, SA News Editor

Intercept Pharmaceuticals (ICPT -0.8%) says it's completed the enrollment for its Phase III clinical trial of obeticholic acid in primary biliary cirrhosis. Results from the 12-month double-blind portion are anticipated to be available in the Q214 and, if successful, will be used to seek regulatory approval of the drug as a second line treatment for the disease.